HIV-related oral lesions · Children and adolescents living with HIV on ART/HAART
Lower CD4+ counts (<250 cells/mm3) were associated with roughly twice the odds of HIV-related oral lesions in two studies (not pooled).
1 finding from 1 review
Oral Health Status of Children and Adolescents Living with HIV Undergoing Antiretroviral Therapy: A Systematic Review… 2022 All outcomesCross-sectional (case-control; single time point) · HIV pediatric/ART clinics, AIDS centers, and hospitals in Brazil, India, Saudi Arabia, and West Africa (Cote d'Ivoire, Mali, Senegal) · CD4+ T-cell count <250 cells/mm3 vs higher
CLWH with CD4+ <250 cells/mm3 were about twice as likely to have HIV-related oral lesions: Baghirath 2013 OR 1.916 (95% CI 0.613 to 2.513), p=0.001; Divakar 2015 OR 1.999 (95% CI 0.129 to 3.688), p=0.001. Not pooled.
2 studies
GRADE not reported
HIV-related oral lesions · Children living with HIV receiving ART
One reported study did not show a clear difference in HIV-related oral lesions for children with CD4+ T-cell counts below 250 cells/mm3.
2 findings from 1 review
OR 1.916 [0.613, 2.513]
1 study
GRADE not reported
OR 1.999 [0.129, 3.688]
1 study
GRADE not reported
Oral mucositis (any severity) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (any severity) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (moderate to severe) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days in hospital · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.
1 finding from 1 review
Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported
Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported